The Heritage of our Business

Biopharmaceutical medicines from mammalian cell cultures have a long tradition at Boehringer Ingelheim BioXcellence™. With a track record of currently 22 launched products, a global network [1] with a commercial bioreactor capacity of more than 280,000 L and a broad variety of cell lines and molecules, we are the preferred partner of our customers [2]  for virtually all their needs in cell line development, process development and clinical and commercial supply.

Global Network of Mammalian Cell Culture Experts

Our global production network [1] gives us great flexibility in transferring processes from our customers [2] to our sites, between sites and between scales. In addition, the combination of our stainless-steel bioreactors (capacity from 2,000 L to 15,000 L each) and our fully disposable single-use bioreactor system (capacity from 100 L to 2,000 L) allows us to work at any scale our customers [2] may need. The disposable system is fully integrated into our manufacturing processes and implemented globally at our cell culture sites in Biberach (Germany) [3], Fremont, CA (USA) [4] and Shanghai (China) [5]. We also constantly add to our capacity, with the investment in a new large-scale cell culture facility in Vienna, Austria [6] as the next milestone. 

For mammalian cell line development, we take advantage of our High Expression Technology (BI-HEX^® CHO-K1), an established high expression technology platform that ensures fast-track development of high-quality, high-titer processes. We use multiple high expression CHO cell lines to produce several mammalian molecule formats and our experience reaches well beyond standard monoclonal antibody (mAb) formats, for example in recombinant proteins and enzymes or multi-specific mAbs. Whether it is formulation, upstream or downstream development:

We have the technology and experience for your cell culture project.

Take advantage of our established high expression technology platform BI-HEX^® CHO-K1 to ensure fast-track development of high-quality and high-titer processes.